CHAMPIONS ONCOLOGY, INC.(CSBR)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-07-31.

CHAMPIONS ONCOLOGY, INC. (CSBR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CSBR at 26.5/100 on a 32-signal composite quality model, placing it at rank #2,620 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include earnings quality (1.3) and revenue scale (10.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 39.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), CHAMPIONS ONCOLOGY, INC. reports quarterly revenue of $15.2M, net income of $-426.0K, an operating margin of -2.7%. Top institutional holders of CSBR by reported 13-F value include Battery Management, NEA Management Company, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CSBR trades on the Nasdaq exchange and files with the SEC under CIK 771856. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CSBR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CHAMPIONS ONCOLOGY, INC. directly from SEC EDGAR.